Loading...
Loading...
- Shares of kidney dialysis provider Fresenius Medical Care AG & Co FMS touched a 52-week low after the company cut its earnings outlook as costs surged and a U.S. staff shortage.
- The company flagged a decline in net income around a high teens percentage range and withdrew its 2025 targets.
- It also expects sales growth at the lower end of the previous forecast range.
- The company reported preliminary Q2 sales of €4.76 billion, +10% Y/Y but almost flat on constant currency.
- Operating income fell 20% to €341 million, while adjusted operating income was up 3% to €445 million.
- Adjusted Net income remained flat at €225 million.
- The company expects pressures from the U.S. labor market to persist in the year's second half.
- It said it no longer expected to achieve organic revenue growth in North American health care services this year.
- New CEO Carla Kriwet will start by October. Rice Powell will step down as CEO effective September 30.
- Price Action: FMS shares are down 14.3% at $19.28 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in